Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes

Authors


  • ANDROMEDA, A raNdomized, Double-blind, double-dummy, multicentre, phase IIIb, parallel-group study to compare the efficacy and safety of Rosuvastatin (10 mg and 20 mg) and atOrvastatin (10 Mg and 20 mg) in patiEnts with type 2 DiAbetes mellitus.

  • Published as an abstract (< 300 words) for the 75th European Atherosclerosis Society Congress, 2005. Citation: Betteridge DJ, Gibson JM, Sager P. Effect of rosuvastatin and atorvastatin on CRP levels in patients with type 2 diabetes: results from the ANDROMEDA study. Atherosclerosis Suppl 2005; 6: 102 (Abstract W16-P-007).

  • Also published as an abstract (< 300 words) for the 64th Scientific Sessions of the American Diabetes Association, 2004. Citation: Betteridge DJ, Gibson M. Effects of rosuvastatin and atorvastatin on non-HDL-C levels in patients with type 2 diabetes: results of the ANDROMEDA study. Diabetes 2004; 53 (Suppl. 2): A227 (Abstract 927-P).

: Professor D. John Betteridge, Endocrinology and Metabolism, Department of Medicine, University College Hospital, London, UK. E-mail: j.betteridge@ucl.ac.uk

Abstract

Aims  To compare the effects of rosuvastatin and atorvastatin 10 and 20 mg on plasma lipid and lipoprotein profiles in patients with Type 2 diabetes mellitus and triglycerides ≤ 6.0 mmol/l.

Methods  A double-blind, randomized, multicentre study to assess the effect of rosuvastatin and atorvastatin, at 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks, on low-density lipoprotein cholesterol (LDL-C), together with a range of secondary lipid and lipoprotein end points.

Results  Rosuvastatin reduced mean LDL-C levels from baseline over 16 weeks by 57.4%, while atorvastatin reduced mean LDL-C levels by 46.0% over the same period. The difference in LDL-C reduction between treatments was statistically significant (P < 0.001). Rosuvastatin also produced statistically significantly greater mean reductions from baseline in levels of total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B and lipid ratios. More patients achieved European LDL-C (< 2.5 mmol/l) and total cholesterol (< 4.5 mmol/l) goals with rosuvastatin than with atorvastatin. Rosuvastatin was associated with a significantly (P < 0.049) greater mean percentage increase in glycated haemoglobin (HbA1c) from baseline compared with atorvastatin; however, patients in both treatment groups maintained good glycaemic control. Both rosuvastatin and atorvastatin were well tolerated.

Conclusions  Greater reductions in LDL-C were achieved with rosuvastatin compared with equal doses of atorvastatin, enabling more patients with Type 2 diabetes to achieve European LDL-C goals.

Ancillary